Emergent says Covid-19 vaccine candidate it is making for Novavax will be ready for trials within four months. Novavax hired Emergent BioSolutions to make the experimental vaccine this week. The vaccine was developed using Novavax’s recombinant protein nanoparticle platform and Matrix-M adjuvant technology. Emergent said it has already started work on making clinical trial supplies of the vaccine, explaining that drug substance will be produced at the Baltimore-Bayview facility while the product itself will be made at its Baltimore-Camden plant.…